Skip to content

Psychiatric Orders in Psychoanalytic Treatment of ASD

Psychiatric Orders in Psychoanalytic Treatment of ASD

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05930912
Enrollment
1
Registered
2023-07-05
Start date
2023-06-01
Completion date
2023-12-01
Last updated
2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD - Combined Type, Agoraphobia With Panic Attacks, Anxiety Disorders, Autism Spectrum Disorder High-Functioning, Avoidant Personality Disorder, Borderline Personality Disorder, Depression and Suicide, Depression, Anxiety, Depression Anxiety Disorder, Depression; Psychoneurotic, Depression, Reactive, Depression, Unipolar, Grief, OCD, Panic Disorder With Agoraphobia, Severe Agoraphobic Avoidance and Mild Panic Attacks, PTSD, Separation Insecurity, Social Anxiety Disorder, Stockholm Syndrome

Brief summary

Autism Spectrum Disorder (ASD) is often accompanied by a variety of other symptoms, such as bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), Social Anxiety Disorder (SAD), Avoidant Personality Disorder (AvPD), Obsessive Compulsive Disorder (OCD), etc. The behavioral and social complications often marginalize the population, impact on life satisfaction, undermined societal values that impact on economic and financial fairness, and so forth. Furthermore, persons with ASD are neurodiverse from standardized pharmacological and clinical cares, and are interpreted disadvantaged in the context of neurotypical treatments. The research protocol aims to differentiate the neuropharmacological implications of ASD from its behavioral and social implications. Such a differentiation is beneficial to the quality of care for neurodiverse population, both in terms of precision treatment in medical settings, and in terms of psychotherapeutic treatment efficacy in the interpretation of behavioral and social traits. The study protocol continues from the adverse event of the participant in NCT05711810 trial, after the positive immunological results in the NCT05839236 trial. The intervention medicine continues from Sertraline adjusted on the choice of Selective Serotonin Reuptake Inhibitor (SSRI) in the previous two trials for complex post-traumatic stress disorder (CPTSD) of the participant, and its combined used with Duloxetine in the choice of Selective Norephedrine Reuptake Inhibitor (SNRI) for norephedrine regulations. The hypothesized target is on the discrete psychiatric intervention centered approach to ASD treatment care. In the PRC where the study is being carried out, amphetamine class medicines are strictly prohibited and defined as illegal substances, regardless of their only proven effect for ASD patient care. Contributed by the sociostructural elements and necessities, black market amphetamine and ketamine have not only emerged in the regime for decades, but also have become a lucrative business. Their recreational uses are also sometimes accompanied by real necessities and needs; black markets cater to the needs but guidance on the usages is based on word-of-mouth stories without professional medical assistances. There is one case the Principal Investigator (PI) collected, that one person, possibly under depression contributed by PTSD, took relatively high dosage of amphetamine and went into a state of psychosis with overwhelming persecution mania. The study protocol, Psychiatric Orders in Psychoanalytic Treatment of ASD, is therefore designed for an evidence-based approach in treating complex psychiatric disorders with psychoanalytic guidance.

Interventions

DIAGNOSTIC_TESTPsychoanalysis

Case-specific psychoanalysis is performed, including the participant's background during birth.

DRUGsertraline 50mg

After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.

Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.

BEHAVIORALCognitive Behavioral Therapy

CBT is tailored to the participant's current activities and life decisions.

Sponsors

S for Science
CollaboratorUNKNOWN
Yang I. Pachankis, PhD
Lead SponsorINDIV

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years

Inclusion criteria

* Persons with ASD.

Exclusion criteria

* Severe ASD cases with central nerve system complications.

Design outcomes

Primary

MeasureTime frameDescription
Behavioral Satisfaction Questionnaire (Y axis)90 daysThe Y axis score total range -200 to +195, from inhibition to excitation of the hypothalamic-pituitary-adrenal (HPA) axis in daily lives.
Young Schema Questionnaire (YSQ)90 days
Personality Belief Questionnaire (PBQ)90 days
Behavioral Satisfaction Questionnaire (X axis)90 daysThe X axis score total range -150 to +140, from self-centrism (passive-aggressiveness) to proactive social behaviors.
Hamilton Anxiety Rating Scale (HAM-A)90 days
Generalized Anxiety Disorder (GAD-7)90 days
Dissociative Experiences Scale - II (DES-II)90 days
The Defeat Scale (D Scale)90 days
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)90 days
Severity Measure for Agoraphobia-Adult90 days
BPD Check List90 days
Rosenberg Self-Esteem Scale (RSE)90 days

Secondary

MeasureTime frameDescription
Systolic Blood Pressure90 daysSystolic blood pressure is measured for reference on psychoneurotic correlations.
Diastolic Blood Pressure90 daysDiastolic blood pressure is measured for reference on possible side-effects with dizziness etc.
Heart Rate90 daysHeart rate is used to correlate to the participant's mode change.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026